In release, the lab reveals that the vaccine prevents 70 percent of people from developing the disease caused by the new coronavirus, according to provisional results of the phase 3 tests that proved that effectiveness resulted from the combination of two dosing regimes: one was 90 percent effective and the other 62 percent.
These are interim results from large-scale clinical trials developed in the UK and Brazil, says AstraZeneca. But in relation to the data already available, this vaccine has a lower efficacy rate than those of Pfizer / BioNTech or Moderna, which exceed 90 percent.
“The results of an interim analysis of the clinical trials of AZD1222 showed that the vaccine was highly effective in preventing Covid-19, its primary objective, and no hospitalizations or severe cases of the disease were recorded in the participants who received the vaccine. A total of 131 cases of Covid-19 were recorded in the provisional analysis “, read in the AstraZeneca statement.
Researchers involved in the production of this vaccine also pointed out that the vaccine “it is effective in preventing many people from getting sick and has been shown to work well in different age groups”.
The pharmaceutical company adds that effectiveness may even reach 90 percent “under a dosage regimen”.
“The efficacy and safety of this vaccine confirm that it will be highly effective against Covid-19 and will have an immediate impact on this public health emergency,” said Pascal Soriot, AstraZeneca’s CEO, in the statement.